☆ 4.7 Meeting Abstract

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

BLOOD (2016)

Get Full Text
Add to Collection

Journal

BLOOD
Volume 128, Issue 22, Pages -

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.V128.22.233.233

Keywords

-

Categories

Hematology

Funding

  1. Pharmacyclics, LLC, an AbbVie Company
  2. Janssen
  3. AbbVie
  4. Gilead Sciences
  5. ARIAD
  6. Gilead
  7. TG Therapeutics
  8. Acerta
  9. Seattle Genetics
  10. Pharmacyclics
  11. Genentech
  12. Novartis

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.